Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358 Krummel, 1996, CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells, J Exp Med, 183, 2533, 10.1084/jem.183.6.2533 Zha, 2004, Negative regulation of T-cell function by PD-1, Crit Rev Immunol, 24, 229, 10.1615/CritRevImmunol.v24.i4.10 Ribas, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, Lancet Oncol, 16, 908, 10.1016/S1470-2045(15)00083-2 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med, 372, 2006, 10.1056/NEJMoa1414428 Lynch, 2012, Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study, J Clin Oncol, 30, 2046, 10.1200/JCO.2011.38.4032 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 Izzedine, 2014, Kidney injuries related to ipilimumab, Invest New Drugs, 32, 769, 10.1007/s10637-014-0092-7 Fadel, 2009, Anti-CTLA4 antibody-induced lupus nephritis, N Engl J Med, 361, 211, 10.1056/NEJMc0904283 Thajudeen, 2015, Ipilimumab granulomatous interstitial nephritis, Am J Ther, 22, e84, 10.1097/MJT.0b013e3182a32ddc Forde, 2012, Ipilimumab-induced immune-related renal failure—a case report, Anticancer Res, 32, 4607 Voskens, 2013, The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network, PLoS One, 8, e53745, 10.1371/journal.pone.0053745 Mae H, Timbol MD, Shirali AC. Acute interstitial nephritis from anti-PD1 therapy with pembrolizumab in two patients with advanced non-small cell lung cancer. [TH-P01051] Abstract presented at: Kidney Week, American Society of Nephrology, November 5, 2015; San Diego, CA. Clarkson, 2004, Acute interstitial nephritis: clinical features and response to corticosteroid therapy, Nephrol Dial Transplant, 19, 2778, 10.1093/ndt/gfh485 Gonzalez, 2008, Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis, Kidney Int, 73, 940, 10.1038/sj.ki.5002776 Muriithi, 2014, Biopsy-proven acute interstitial nephritis, 1993–2011: a case series, Am J Kidney Dis, 64, 558, 10.1053/j.ajkd.2014.04.027 Ryder, 2014, Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution, Endocr Relat Cancer, 21, 371, 10.1530/ERC-13-0499 Tivol, 1995, Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4, Immunity, 3, 541, 10.1016/1074-7613(95)90125-6 Nishimura, 1999, Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141, 10.1016/S1074-7613(00)80089-8 Zheng, 2005, The role of tubulointerstitial inflammation, Kidney Int Suppl, S96, 10.1111/j.1523-1755.2005.09423.x Spanou, 2006, Involvement of drug-specific T cells in acute drug-induced interstitial nephritis, J Am Soc Nephrol, 17, 2919, 10.1681/ASN.2006050418 Maripuri, 2009, Renal involvement in primary Sjogren's syndrome: a clinicopathologic study, Clin J Am Soc Nephrol, 4, 1423, 10.2215/CJN.00980209 Spain, 2016, Management of toxicities of immune checkpoint inhibitors, Cancer Treat Rev, 44, 51, 10.1016/j.ctrv.2016.02.001 Weber, 2016, Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab, Cancer Immunol Res, 4, 345, 10.1158/2326-6066.CIR-15-0193 Horvat, 2015, Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, 33, 3193, 10.1200/JCO.2015.60.8448 George, 2011, Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia, Oncology (Williston Park), 25, 908 2012, KDIGO clinical practice guideline for acute kidney injury, Kidney Int Suppl, 1 Dewitte, 2015, Kinetic eGFR and novel AKI biomarkers to predict renal recovery, Clin J Am Soc Nephrol, 10, 1900, 10.2215/CJN.12651214 2009 Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006